First AD

Second AD

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

The Effects of Real-World Evidence on the Treatment of HER2+ mBC

Jane Meisel, MD, elaborates on the evolution and significance of the antibody-drug conjugate trastuzumab deruxtecan in treating HER2+ metastatic breast cancer, highlighting its effectiveness and considerations for its usage.

The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC

Evolution of Advanced HER2+ Breast Cancer Management

Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)

Approaches to Sequencing Therapies for HER2+ mBC

Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC

Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC

Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment

Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)

Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

Novel Therapies Under Investigation for HER2+ mBC

Treatment Sequencing Approaches for Patients With HER2+ mBC

French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC

Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC

Treatment Approaches for Patients With HER2+ mBC and Brain Metastases

Novel Treatment Approaches Under Investigation for HER2+ mBC